Leqembi is not known to interact with alcohol, other drugs, or supplements. However, the drug has some health-related interactions. Talk with your doctor to avoid potentially harmful effects from ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier ... did not outweigh the risk of side effects. Meanwhile, recent reimbursement ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

the launch of the Alzheimer's disease drug developed by Biogen Inc. and Eisai Inc. has been criticized for being slow. For instance, William Blair analysts said the U.S. launch of Leqembi was ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration ...

Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive Impairment or mild dementia stage of the disease. A Prescription Drug User Fee Act (PDUFA) action date is August 31, 2025.